Five Non-Magnificent Seven Stocks Avert S&P 500 Correction

Non-Magnificent Five Bolster S&P 500 Amid Correction Fears

Eli Lilly ($LLY), Broadcom ($AVGO), JPMorgan Chase ($JPM), Visa ($V), and UnitedHealth Group ($UNH) have collectively added more than $450 billion to their market capitalization in the last four weeks, serving as a critical buffer against a potential S&P 500 ($SPX) correction. This concentrated strength from a diversified group of large-cap stocks has stabilized the broader market.

This robust performance has kept the benchmark S&P 500 ($SPX) just 1.8% below its March 28 all-time closing high of 5,254.35. The index has avoided a 5% pullback, which often precedes a more significant technical correction, even as nearly 60% of S&P 500 components have experienced a decline of 10% or more from their 52-week peaks.

Market Impact

The five stocks have demonstrated remarkable resilience and growth. Eli Lilly ($LLY) has climbed approximately 12% in the past month, primarily driven by strong demand for its weight-loss drug Mounjaro. Broadcom ($AVGO) saw an 9% increase, supported by robust enterprise demand for its semiconductor and software solutions. JPMorgan Chase ($JPM) advanced 7%, benefiting from strong net interest income forecasts and resilient consumer spending. Visa ($V) gained 6% on consistent payment volume growth, while UnitedHealth Group ($UNH) surged 10% after addressing regulatory concerns and reaffirming its full-year outlook.

This collective uptrend sharply contrasts with the mixed performance of some 'Magnificent Seven' constituents, such as Tesla ($TSLA), which declined approximately 15% in April, and Apple ($AAPL), which faced pressure with a 5% dip over the same period. The combined contribution of these five non-Magnificent Seven stocks has effectively offset a significant portion of the broader market's weakness, which saw the average S&P 500 stock, excluding the top 10 by market cap, fall by 4.2% in April. This marks the first time since late 2022 that a non-tech dominant group has shown such collective outperformance in the face of broader market weakness.

The shift indicates a potential rotation of capital, with investors seeking stability and diversified growth outside of the heavily concentrated technology sector. This dynamic could lead to a more balanced market, potentially drawing funds from riskier assets or heavily concentrated tech positions. In the fixed-income market, the stability provided by these equity heavyweights has contributed to a slight moderation in Treasury yields, with the 10-year U.S. Treasury yield ($US10Y) retreating to 4.58% from its recent peak of 4.70% on April 25, as some flight-to-safety capital found a home in these resilient equities.

What Analysts Are Saying

Market strategists are beginning to acknowledge this broadening of market leadership. "The market is finally broadening out, moving beyond the narrow leadership we've seen," stated Michael Wilson, Chief U.S. Equity Strategist at Morgan Stanley. "This cohort of five companies represents a significant shift, indicating healthier underlying market dynamics and reducing the S&P 500's reliance on just a handful of tech giants."

David Kelly, Chief Global Strategist at J.P. Morgan Asset Management, offered a more nuanced perspective. "While encouraging, investors should scrutinize the individual drivers of these stocks, from new drug pipelines for Eli Lilly to chip demand for Broadcom, rather than assuming a uniform trend," Kelly noted. "Their collective strength is a positive sign, but it doesn't negate the need for fundamental analysis of each company's prospects."

However, not all analysts are convinced this trend will entirely mitigate broader macroeconomic risks. Strategists at Bank of America Global Research cautioned, "While these stocks offer a temporary reprieve for the S&P 500, persistent macroeconomic concerns, particularly sticky inflation data and higher-for-longer interest rate expectations, could still trigger a broader market drawdown that even these heavyweights might struggle to fully offset." They highlighted the potential for renewed volatility if upcoming inflation reports surprise to the upside.

What to Watch

Investors should closely monitor several key catalysts and economic indicators. Upcoming earnings reports and forward guidance will be crucial, particularly for Eli Lilly ($LLY) on May 2, and Broadcom ($AVGO) expected in early June, which could provide further insights into their growth trajectories and market demand. Positive outlooks could reinforce their leadership, while any disappointments might temper enthusiasm.

Macroeconomic data, especially the Consumer Price Index ($USCPI) report on May 15 and subsequent Producer Price Index ($USPPI) releases, will be vital for gauging inflation trends and their potential impact on Federal Reserve policy. Sustained high inflation could reignite concerns about interest rates, potentially dampening overall market sentiment. Conversely, signs of moderating inflation could provide further support for a broader market rally.

Key S&P 500 ($SPX) technical levels to watch include immediate resistance at 5,250, a level that has proven challenging to break decisively. On the downside, the 5,100 level represents significant support. A sustained break below 5,100 could signal renewed downside risk and potentially lead to a retest of the 5,000 psychological level. Continued sector rotation, specifically capital flows into healthcare ($XLV) and financials ($XLF) ETFs versus technology ($XLK), will also indicate whether this broadening of market leadership is a durable trend or a temporary phenomenon.